EVAX Evaxion A/S

NASDAQ
$2.54

Evaxion A/S Q3 F2026 Earnings Call Transcript

AI Conference Call Analysis

Sign in or subscribe to read.
Conference Operator
Operator
Good day and thank you for standing by. Welcome to the evaxion strategy and business update and third quarter 2026 financial results webcast and conference call. At this time all participants are in a listen only mode. After the speaker's presentation there will be a question and answer session. To ask a question during the session you will need to press star 1 and 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 and 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Helen Tayton-Martin, CEO. Please go ahead.
Helen Tayton-Martin
CEO
Thank you, and good morning and welcome to everyone to ABACTION's Strategy and Business Update for Q3. I'm Helen Tayton-Martin, I'm the CEO of Avaction and I'm joined today on the call by Birgitte Rono, our CSO and COO, and Thomas Schmidt, CFO, Mads Kronborg, our Head of IR and Communications. In our agenda today, I will walk you through how we are refocusing our strategy to create the maximal value and we'll then hand over to Birgitte who will take us through the highlights of our R&D activities during the quarter. and some of the key data and developments with our AI immunology platform which is driving this strategy shift. Thomas will take you through the financial results for the quarter before we wrap up with some concluding remarks and take questions. As a reminder, we may make forward-looking statements during today's call and in that context I would refer you to our most recent final statements. So, turning to the first agenda point, our strategy update. Put very simply, Avaction is now refocusing all of its own resources in the application of our AI immunology platform towards our oncology portfolio. With Moderna's recent Phase 3 groundbreaking data validating personalized cancer vaccines as truly capable of delivering meaningful clinical benefit in adjuvant melanoma, we have been proud and excited to share our own Phase 2 three-year clinical data in recent weeks in which patients with metastatic melanoma where we use our AI Immunology platform to predict high quality and relevant antigens for patients which is correlated with high precision in terms of the immune response generated and more importantly in deep and durable outcomes as Birgitte will highlight later. In addition, we have been able to use AI Immunology to drill deeper into the dark genome and identify other types of antigen, especially endogenous retroviral elements or ERNs where we can identify unique and highly conserved sets to enable an off-the-shelf vaccine approach, in addition to the personalized neo-antigen vaccine. We believe there is enormous opportunity in Avaction's AI immunology platform to identify and develop both personalized and off-the-shelf cancer vaccines across multiple indications, customized according to antigen source and scope. And this is where maximum value lies in Avaction. As a result, going forward, we will be focusing our own resources in the three key areas shown at the bottom of this slide. Firstly, taking our two off-the-shelf cancer vaccines, EVXO4 in AML and EVXO5 in GBM, into the clinic, the latter in collaboration with Duke University. Secondly, we'll be looking at broadening the potential of EVXO1 beyond advanced melanoma, and most likely we expect to do this through partnership. And thirdly, We plan to continue to identify other new antigens and indications from deeper analysis of the dark genome with AI immunology. In terms of our pipeline going forward, we will be progressing only our oncology assets, as just mentioned. But elsewhere, we believe we have built significant value in the preclinical assets and capabilities we have developed in the infectious disease area over many years. With EVXB1 in Staph aureus, EVXB2 in gonorrhea, EVXB4 in Group A Streptococcus and EVXB1 in CMV. And so we will continue to look for partnership for these assets and work with partners only in other infectious disease programmes where the partner comes forward. In autoimmune disease, we are testing the concepts we identified for tolerogenic vaccines and autoantibody binders using AI immunology and we'll complete that work to validate the approach for potential partnering. So looking to the achievements we have made in the last quarter on business development we've had a very busy time and continue to progress multiple parallel conversations all leveraging the recent data and validation of AI immunology with the EVXO1 and the future off-the-shelf potential with EVXO4 and 5 and more broadly with other cancer indications. On RMD much of the latest three-year data for EVXO1 was presented at ESMO and CITSE as Birgitte will cover and we will be providing a further update for the EVXO4 programme at ASHE next month. We completed the initial work with Adaspia before Group A strep programme and started the initial concept testing from the targets identified for autoimmune disease. On the platform itself, we were truly honoured to see AI Immunology recognised on the international stage at the International Galien Awards, winning the Best Digital Health Solution Prize We believe adding further validation to how the Evaction AI platform delivers meaningful, beneficial benefits. And finally, we have continued to maintain rigorous discipline in managing our financial resources aligned to the greatest areas of value, as well as being able to make prudent use of our ATM to enable us to extend the runway towards the end of 2027. When we look at our milestones for 2026, we have now achieved all of them except for the filing of our EVXO4 clinical trial application. but this is on track to be filed by the end of the year in keeping with our refocus strategy on our IO programs and capabilities.
Dania Ben-Hale
Analyst, Jones
And with that, I will hand over to Birgitte to take us through the key R&D and AI immunology updates.
Birgitte Rønø
CSO and COO
Thank you for that, Helen. And as Helen outlined, we are focusing our strategy on oncology, building on the clinical and translational evidence from our personalized EVX01 cancer vaccine and the broader capability of our proprietary AI platform, AI Immunology, to discover clinically relevant cancer antigens and to design vaccines. So our priorities are, as mentioned, to advance our off-the-shelf cancer vaccines, EVXO4 and EVXO5, toward clinical development and further to expand EVXO1's potential across indications through partnerships and to continue mining the dark genome for cancer vaccine antigens. So the scientific update that follows show the evidence behind this focus and how we are translating our AI platform's capability into oncology product opportunities. So let me start with the rationale behind personalized cancer vaccines. Personalized cancer vaccines targets new antigens These are sequences that are rising from cancer-specific mutations, and they're found exclusively in the tumor but absent in normal tissue, making them highly attractive to therapeutic targets. So the challenge lies in identifying which of the patient's new antigens that will generate a tumor-targeting immune response. So AI Immunology selects the most promising new antigens by modeling the steps from cancer-specific mutations through expression, translation, presentation on the MHC molecules, and T cell recognition. And the AI Immunology platform sits within a broader patient to vaccine process. So for each patient, tumor and blood samples are collected and they undergo DNA and RNA sequencing. AI Immunology then, based on this information, predicts the patient-specific new antigens in 24 hours, informing the design of the personalized EVXO1 vaccine. Following manufacture, the vaccine is then administered in combination with checkpoint inhibitors. And the total turnaround time from biopsy to vaccine administration is approximately seven weeks. So in our EVXO1 phase two study, we reported a 89% position in predicting immunogenic new antigens. And I'll now turn to the clinical results and the immune response data behind this record high position. So in our EVX01 Phase II study in advanced melanoma, the two-year results showed an objective response rate of 75% and a complete response of 25%. We also saw improvement in the response from a week 12 assessment following initiation of EVX01 immunization. So seven out of 13 patients who had stable disease or a partial response after 12 weeks of anti-PD-1 therapy improved their response corresponding to 54% following EVX01 administration. Also of importance is that EVX for one related adverse events were limited to grade one and grade two. So the one year extension provided longer follow up in a smaller group of patients and the clinical responses in all six patients who participated in this extension with EVXO1 monotherapy lasted until the end of the trial. So overall, these are very encouraging clinical results that demonstrated clinical benefit of EVXO1 in combination with anti-PD1 therapy in advanced melanoma. Turning to immunogenicity, EVXO1 induces potent vaccine-specific T-cell responses against the vaccine-new antigens. And the key point is that the platform can identify antigens recognized by the immune system. So EVXL1 induced vaccine-specific T cell responses that are sustained throughout the three-year period, including in the absence of anti-PD-1 therapy, which is provided only or was provided only during the first two years. And as mentioned, we were able to demonstrate a record high vaccine target precision of 89% that is a clear testament to the predictive power of our AI immunology platform. And additionally, 86% of the assessed new antigen responses were de novo. In other words, newly induced responses rather than preexisting responses. And this is important as therapy-induced new T cells have been correlated to clinical benefit. So let's look more closely at the phenotype of the T cell responses and how the strength of the EVXL1 induced T cell responses relates to AI predictions. So first, EVXL1 induces both CD4 and CD8 positive antigen-specific T cell responses. In all evaluated patients, we were able to demonstrate a CD4 positive response and in nine out of the 15 patients, we were also able to detect CD8 responses. And we are still evaluating samples from the study, so stay tuned, more immune data will be, and biomarker data will be shared in the next year. So secondly, we were able to demonstrate a positive correlation between the AI prediction score assigned to these single new antigens, and that is and the magnitude of the observed immune response. So higher prediction score also were associated with a stronger immune response. And this is an important link between the platform's predictions and the biological responses measured in the patients. So with that clinical and translational foundation, let's look at how AI immunology can be applied more broadly. So the broader opportunity is to use AI immunology across antigen sources, cancer indications, and vaccine approaches. So the platform processes the complex patient data, including genomic, transcriptomic, and proteomic data, to identify and prioritize cancer antigens. And as shown here, our work spans new antigens and endogenous retrovirus, or ERVs, from that genome, and we are now looking at additional stark genome antigens. And that creates two complementary vaccine approaches, personalized vaccines that are tailored to an individual patient and targets private antigen as exemplified by EVX01 in melanoma. And then off the shelf vaccines that are tailored to a patient population and target conserved as in EVX04 for acute myeloid leukemia and EVX05 for GBM. The other indications shown on this slide, including head and neck, lung, ovarian, bladder, colon, esophageal, testicular, and stomach cancers, illustrate the potential breadth of the application based on deep data mining and antigen profiling of patients. and the strategic point is that the platform is not confined to one cancer type or to one vaccine approach. It gives us basis for pursuing opportunities across personalized and official cancer vaccines. So let's now look at AI immunology's key differentiators. So broad discovery across multiple antigen sources and high target precision. and that translate into strategic product opportunities for both personalized and off-the-shelf cancer vaccines across small patients and cancer types. So AI Immunology, as mentioned, explores new antigens from cancer-specific somatic mutations, antigen from genome-integrated viral sequences and additional dark genome antigens which are currently in development. and this provides a broader antigen repertoire. So with our record high target position demonstrated in clinical trials, exemplified by the 89% vaccine target position rate in EVX-01 Phase II trials, we are well positioned in finding the right targets. And the core component of AI immunology is instrumental in identifying the most relevant and this one is a key driver of the high target precision rate. The core code is antigen type agnostic and provides a common foundation for designing high precision cancer vaccines irrespectable or irrespective of the antigen of choice. So these two AI immunology differentiators broad antigen repertoire and high target precision translate into strategic and Dr. Michael Schmitz. So greater antigen breadth significantly increases the chance of finding effective targets for more patients and cancer types. And the physician at the target level increases the likelihood of clinical success as it is the foundation for stronger clinical outcome. So taking together these positions, AI and immunology, not just as a platform for a single vaccine, but as a foundation for developing a broader portfolio of cancer vaccines, combining the opportunity to reach more patients with a potential for stronger clinical outcomes. So EVX-04 is a concrete example of how we are translating this broader discovery capability into an official Cancer Vaccine Program. So starting with sequencing data from AML patients, we identified ERV tumor antigens. And from 5 million ERV antigen fragments and corresponding MIT ligands, AI Immunology selected the 16 optimal antigen fragment sets. Currently multiple vaccine candidates were assigned and tested and the lead candidate is now moving forward in GMP manufacturing. And we are now progressing through final preclinical testing and validation of the selected herb antigens alongside activities to enable clinical trial application or CTE. and with a submission expected in the second half of this year. So in summary, AI immunology combines broad antigen discovery without high target position and we can identify cancer antigens from multiple sources, new antigen herbs and additional dark genome antigen approaches in development using the same core predictive technology across antigen sources. Together, these capabilities create the opportunity to identify relevant targets for more patients and more cancer types, supporting both personalized and off-the-shelf approaches and providing a foundation for a stronger clinical outcome. So with that, I'll hand over to Thomas to present our Q3 financial results.
Thomas Schmidt
CFO
Yes, thank you Birgitte and also a warm welcome from my side to everyone on the call. Let me take you through the financial results for Q3 and we shift to the financial highlights. So as key financial highlight for the quarter, we have now successfully further extended our cash runway now towards the end of 2027. This is from earlier communications that we've done where we spoke about cash runway into the second half of 2017. This we've managed to do through first and foremost utilizing our ATM program. However, also through our continued disciplined resource allocation. and both the ATM and certainly also our continued discipline resource allocation is also in support of our now refocused strategy and the updated pipeline as we have just heard and seen. We are on track for the full year to deliver according to our financial plan. and we also still expect an unchanged yearly cash burn rate of approximately 14 million dollars as also earlier communicated. Cash position obviously have improved throughout the year and now also reflects that in the extended runway. Looking into our profit and loss details, the statement clearly shows a net loss for the quarter of $3.5 million, which compares to 4.6 million profit in the same quarter last year. Main reason for that lies within the recognized revenue. We've not recorded any recognized revenue in Q3 this year, whereas last year we outlicensed our EVX B3 program to Merck, or as called in Europe, MSD. At the same time, however, this year we have reduced our operating costs compared to last year. both within R&D due to fewer headcounts but also in G&A with lower capital market costs while we at the same time have put more resources into BD business development activities and therefore costs. Our financial income and expenses for the quarter also now reflect a more normalized financial operation of ours where the financial expense and income relate to interest from our debt and interest from income from our bank and cash position. This compares to last year where we had high financial income from our debt to equity agreement that we did with the European Investment Bank. and on the other side we had financial expenses which related to re-measurement of our derivative liability. This derivative liability has been reduced significantly and has no longer any significant impact on our financial expenses and income. Moving to our balance sheet. Our main balance sheet items include obviously our cash position now end of September of $13.3 million. This includes proceeds from our ATM program of $2.2 million, which we utilized and received in August 2026. We have received further proceeds from our ATM program in October of another $800,000, but that is not reflected in the cash position end of September. However, it is included in our cash runway that, as mentioned earlier, has now been extended towards the end of 2027. Equity stands at $8.1 million, which obviously also has been increased by the ATM sales in August and obviously impacted by the net loss from the period also. Last, but also not least, even though it is in November, important just to note also that we have filed an amendment to the form F1 which relates back to 2025 that settled agreement with the European Investment Bank which now this new amendment allows them to exercise their warrants. It's important to note that we are not selling any securities under this registration and we will not receive any proceeds from the We have received back in 25 and recorded a debt cancellation of 4.1 million dollars in exchange of warrants. And these warrants once exercise will mean that we may receive up to another 1.5 million US dollars. when and if exercised by the European Investment Bank. With that, I conclude the financial for the quarter and hand it back to Helen for some concluding remarks.
Helen Tayton-Martin
CEO
Thanks, Thomas. So in concluding, I think today we have set out a refocus strategy to maximize the value of our assets and capabilities in immuno-oncology, and we have set out why we are planning to do that and how we are planning to do that. In particular, we've seen continued valued validation of the unique capabilities that Avaction has in AI immunology, as well as commented on how that impacts and drives forward individual programs. Business development remains a key priority for the organization with multiple parallel conversations ongoing, and we have been able to extend the runway towards the end of 2027. all of which is putting it actually into a strong position as we complete our mass sends at the end of 2026. So with that, I think we will finish the call. Thank you for listening and be ready to take questions.
Conference Operator
Operator
Thank you. To ask a question, you will need to press star one and one on your telephone and wait for your name to be announced. To withdraw your question, please press star one and one again. One moment for our first question. And this one comes from Thomas Flaten from Lake Street Capital Markets. Please go ahead.
Thomas Flaten
Analyst, Lake Street Capital Markets
Thanks for taking the questions. Helen, just to follow up on the beginning of your prepared comments, you noted the enthusiasm in the market following the Merck Moderna data at ESMO. So just looking back at the pivot that you're undertaking, Was there a lack of interest on the infectious disease side or has there just been overwhelming interest on the immuno-oncology side which is part of the reason for the pivot or was it simply a lack of resources that puts you in the position of focusing on one versus both?
Helen Tayton-Martin
CEO
I think it's really the overwhelming interest that we are seeing in our immuno-oncology capabilities and the breadth of those as Birgitte explained very eloquently that there is just, we have a lot more validation and we have a lot of opportunity. It's not that we don't believe in the infectious disease assets and capabilities, it's just really where the momentum and the most significant value for what Avaction has created and can do. I think it's very clear to us, very clear from the dialogue we have had going on externally, and so if we didn't believe in the infectious disease assets we already have, we wouldn't be still continuing to talk about them with partners. We believe there's value there. This is really about maximizing our own current resources around where we can see a lot of engagement and opportunity. I hope that answers the question.
Thomas Flaten
Analyst, Lake Street Capital Markets
That's great. And speaking of partnerships, Any news we can anticipate from the ongoing collaboration with Merck on the infectious disease side?
Helen Tayton-Martin
CEO
Not that I can share today.
Thomas Flaten
Analyst, Lake Street Capital Markets
Okay. And then just one for Birgitte. Have you guys looked at, and you may have presented this in the past, and I apologize if you have, the correlation between CD8 response and clinical response? Given that you had broad-based CD4, we can kind of write that off as a universal response. But what about the CD8 correlating to clinical response?
Birgitte Rønø
CSO and COO
I'll let Regina take that one. Yeah, no, it's a really good question. So for the few patients that are not responding to study therapy, we actually do not have a strong immune data set because they are early progressors. So I cannot, I would say the data set we have available currently cannot fully answer that question.
Thomas Flaten
Analyst, Lake Street Capital Markets
Got it, appreciate it. No, no, no worries. Thanks for taking the questions.
Conference Operator
Operator
Thank you. Thank you. We are now going to take the next question. And this one comes from Jason McCarthy from Maxine Group. Please go ahead.
Michael Okunowich
Analyst, Maxim Group
Hey, guys. Good morning. This is Michael Okunowich. I want to see if you could talk just a little bit about the expansion strategy for EBX01, and is this something where you would need to do some smaller proof of concept or preclinical work and then seek partners or is the melanoma validation itself sufficient to support expansion in those partner discussions?
Helen Tayton-Martin
CEO
Great question. We believe and certainly the engagement that we have is very much around the validation we've already seen in advanced melanoma, which I think is a distinction for the election platform and clinical data. I think what we can also, what we've been able to highlight is where, as Birgitte showed on the slide, that we have already done quite a bit of work to look at other indications that are potentially possible with the UVXO1 approach alone. I think what's also interesting to us and to partners is We can go beyond neoantigens in a personalized setting. So there could be indications where a combination of personalized and of is feasible. And that doesn't really change the process of making and delivering the vaccine. So it opens up opportunity for where we currently are. So we can take the current clinical package. We can take the ability of AI immunology to derive neoantigens and other antigens and potentially move forward quickly into other initial, potentially phase two settings in other indications. And I think that's a real advantage from where we are right now. And so those are the sort of issues and questions that we're looking at in terms of where's the best opportunity and how to broaden out scope. So again, lots of opportunity. It's working through best fit, best setting, best antigen.
Michael Okunowich
Analyst, Maxim Group
Thank you. And then just with the strategic refocusing, how does that impact your plans for the autoimmune platform? Are you still planning to build this out, given that it is early along in that value creation pipeline and likely requires less resources versus clinical stage assets?
Helen Tayton-Martin
CEO
Yeah. Great question. And we are planning to complete. We have set out to identify the right targets for concept testing in autoimmune disease. Obviously we're looking at ways of reducing immune inflammation in different settings and that concept testing has progressed. We anticipate completing the validation of that research, the work in the labs to do some testing around those concepts and I think we plan to at least complete that work to see whether we can show a compelling case for how we would take those programs forward, and again, potentially with partnerships. So it's not requiring additional resource at the moment, and we plan to complete that work so that we can actually talk more about the scope for AI immunology to deliver in the autoimmune space. So that's ongoing. That won't stop right now.
Michael Okunowich
Analyst, Maxim Group
Thank you. And then just one follow-up on that one, and I'll hop back into the queue. When thinking about that validation work that you need to get a partnerable package, what does that actually entail? Would this be producing an IND-ready product candidate for a specific disease, more along the lines of target discovery? I'm trying to understand what level of validation you need before you can bring it to partners.
Helen Tayton-Martin
CEO
I think that depends. I'll ask Birgitte to just comment on thoughts about where we are. The value of what we think we can generate, but I think we'll be early, basically.
Birgitte Rønø
CSO and COO
Yeah, we have so far developed two therapeutic concepts. One is a telegenic vaccine that aims at re-educating the immune system towards self-tolerance. And the AI immunology team and the bioinformaticians have worked on this concept. We are slowly getting ready in the lab to test some of these concepts. and then we have the other therapeutic approach which is based on an antibody binders and that is with the aim of reducing levels of pathogenic autoantibodies. We have started talking about these concepts and presenting at different conferences so we hope that they will be able to at least get some interest from potential partners early on So before even having a defined product candidate.
Conference Operator
Operator
That's really early proof of concept.
Michael Okunowich
Analyst, Maxim Group
All right. Thank you very much. I appreciate the additional clarity.
Conference Operator
Operator
Thank you. Thank you. We're now going to take the next question. and this one comes from Charles Wallace from H.C. Wainwright. Please go ahead.
Charles Wallace
Analyst, H.C. Wainwright
Hi. Thanks for taking my question. So maybe the first from me. So, you know, now with the two positive phase three cancer vaccine readouts in the field, you know, InterPath 01, an adjuvant melanoma, and then just two days ago, the Regal study and transplant-ineligible AML. So I'm just curious. regarding your pipeline, where is the interest specifically? Is it more in a personalized vaccine approach or in the off-the-shelf vaccine approach? That's my first question, thank you.
Helen Tayton-Martin
CEO
Okay, I would definitely say it's in both to the extent that we can share anything at all at this stage. I think that the broader potential across indications is definitely of interest, but clearly there are advantages in an off-the-shelf are all interested in vaccine in terms of simpler supply chain, simpler delivery, simpler ability to deliver a product. And that's obviously of significant interest. However, at this point, that's not clinically validated. So there's a belief in the personalized vaccine approach that can deliver clinically. We've shown that. Others have shown that. and off-the-shelf is very much of interest. And it's really about getting, you know, moving along to clinical validation. So, I would say there's equal interest in both areas at the moment.
Charles Wallace
Analyst, H.C. Wainwright
Okay.
Thomas Flaten
Analyst, Lake Street Capital Markets
That's helpful.
Charles Wallace
Analyst, H.C. Wainwright
And then I guess, so on the infectious disease programs, you know, the out-licensed program, EVX-B3, and then also the co-development program of EVX-B2. Can we assume that nothing's really changed in these two programs? Yeah, that's my next question.
Helen Tayton-Martin
CEO
Thank you. So B3 is obviously outlicensed in the cooperation with MSD and is moving forward. So the further updates from that will really come as a result of the MSD activities and the The B2 program is in collaboration with Afrogena on an RNA platform and again, things have continued there. There will be data packages for B2 as with B1 and B4, as well as B1 as I mentioned in my comments that are available for, that we've continued to build on during the course of this year and are available, will be available in those partner in conversations. So from a partner perspective, B3 is moving along with MSD. And in the fullness of time, we'll be able to talk more about that. But that's really driven off the next stages with them. And so things have not moved significantly from our perspective at this point until we hit the next point with that one.
Charles Wallace
Analyst, H.C. Wainwright
Great. Thanks for taking my questions.
Conference Operator
Operator
OK, great. Thank you. We are now going to take the next question. And this one is from Dania Ben-Hale from Jones. Please go ahead. Hi.
Dania Ben-Hale
Analyst, Jones
Thank you for taking your questions. To follow up on the previous ones, can you share if there are any questions, diligence that potential partners have around EVX01?
Helen Tayton-Martin
CEO
Not really, but I can talk to the fact that they were asked all the questions, many questions that would be asked in this setting too, really understanding turnaround time, the depth of the immune responses that we see, the correlations there, the quality of the antigens and the scoring that we generate, really looking very closely given that the whole world, the whole landscape around cancer vaccines has now shifted gears It's really important to understand key scientific differentiators and also platform delivery opportunities where maybe there is scope to reduce the timeframe, they look at the modality of delivery, etc. So all the sorts of things that come with drilling into how a product platform like this works. and then thinking about that more broadly in terms of different indication contexts, which is very much sort of what we are doing too.
Dania Ben-Hale
Analyst, Jones
Thank you. And for the manufacturing, are you working on speeding up the vein-to-vein from the seven weeks that you mentioned?
Helen Tayton-Martin
CEO
We know that it can be done. Birgitte, do you want to comment on the things that we are aware of?
Birgitte Rønø
CSO and COO
Yes. So the way that we have set up the supply chain is in a decentralized manner, meaning that we have been working with multiple different CDM roofs. So there's definitely an opportunity to get all of these many activities under one roof to reduce the manufacturing time. There's also been global shipping. going from the clinical site to the sequencing facility and for the drug product to be shipped back to the clinical site. So this adds up in those overall timelines. So there will be multiple ways that the turnaround time could be significantly reduced.
Conference Operator
Operator
Great. Thank you for that.
Dania Ben-Hale
Analyst, Jones
And last question about EVXO4. When should we get more details on the clinical trial design?
Birgitte Rønø
CSO and COO
So we will be, as Helen mentioned, presenting target validation data at ASH in December. And we are also running fast towards clinical trial application later this year. So at that time point, we will most likely be able to share more details around patient population and trial design.
Conference Operator
Operator
Perfect. Thank you very much. Thank you. Thank you. As a reminder, to ask a question, you will need to press star 1 and 1 on your telephone. That is star 1 and 1 to ask a question. There seems to be no further questions for today. I will now hand the call back to Helen Tayton-Martin for closing remarks.
Helen Tayton-Martin
CEO
Thank you. Thank you very much for listening to our strategy and business update for Q3 today. We are very excited about the path forward for action. Thanks for the questions. Thank you.
Conference Operator
Operator
Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.